2026-10-15 カナダ・ブリティッシュコロンビア大学（UBC）
Histopathology image showing breast cancer cells from a tissue sample. Researchers use this type of analysis to examine changes in tissue structure and identify signs of disease.
＜関連情報＞
- https://news.ubc.ca/2026/10/lactation-drug-could-reduce-breast-cancer-risk/
- https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-26-0187/789379/Cabergoline-Suppresses-Postpartum-Breast-Cancer-by
Cabergoline Suppresses Postpartum Breast Cancer by Enhancing Mammary Gland Involution in Brca1-Mutant Mice and Is Associated with Reduced Risk in Younger Women
Natalia García-Sancha;Roberto Corchado-Cobos;Ryan Ghorayeb;Adrián Blanco-Gómez;Oriol Cunillera;Diego Alonso-López;Nathalie C. Støer;Francesca Mateo;Roderic Espín;Le Tam Nhan Nguyen;Mercè Marzo-Castillejo;Chelsey L. Gough;Katy Milne;Sonia Castillo-Lluva;Javier De las Rivas;Julio Pozo;Alberto Orfao;Luis Palomero;Jaime Pignatelli;Eva Sacristan-Horcajada;Luis Félix. Valero-Juan;Carmen Patino-Alonso;David Perera;Ashok R. Venkitaraman;Jian-Hua Mao;Hang Chang;Alejandro Jiménez-Navas;Manuel Jesús Pérez-Baena;Nélida Salvador;Marina Mendiburu-Eliçabe;Patricia Gonzalez-Garcia;Eduardo Caleiras;Isabel Peset;María Begoña García-Cenador;Francisco Javier. Garcia-Criado;Brad H. Nelson;Edoardo Botteri;Miquel Angel. Pujana;Christopher A. Maxwell;Jesús Pérez-Losada
Cancer Discovery Published:October 15 2026
DOI:https://doi.org/10.1158/2159-8290.CD-26-0187
Abstract
Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk. Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the onset and reduces the incidence of postpartum mammary cancer in K14-Cre; Brca1F/F, Trp53F/F mice. In these mice, cabergoline treatment remodels the mammary gland by potentiating involution, reducing ductal area and proliferation, and reversing T cell exhaustion, potentially through modulation of ion channel expression. Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate 69% reduction in risk. Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.
